The generation of fluorometholone nanocrystal eye drops, their metabolization to dihydrofluorometholone and penetration into rabbit eyes
The generation of fluorometholone nanocrystal eye drops, their metabolization to dihydrofluorometholone and penetration into rabbit eyes
复制标题
DOI:
10.1016/j.ijpharm.2020.120067
复制
发表时间:
2021-01-05
影响因子:
5.8
通讯作者:
Nishida, Kohji
中科院分区:
文献类型:
--
作者:
Baba, Koichi;Hashida, Noriyasu;Nishida, Kohji
Fluorometholone is a widely used anti-inflammatory ophthalmic formulation, which elicits a lower ocular hypertensive response than other glucocorticoid medications. This serves to mitigate against the risk of steroid-induced glaucoma. Based on the hypothesis that an improved corneal permeability can increase the bioavailability of a drug, we sought to obtain fluommetholone in suspension with a small particle size. Accordingly, we describe the formulation of fluommetholone nanocrystal eye drops, which have a mean particle size of 201.2 +/- 14.1 nm (standard deviation (s.d.)) when measured by dynamic light scattering. Scanning electron microscopy further indicates that fluommetholone nanocrystals are predominantly rectangular in shape. Fluorometholone microcrystals, on the other hand, with a mean particle size of 9.24 +/- 4.51 mu m (s.d.), tend to have a rod-like morphology. Powder x-ray diffraction revealed that fluorometholone microcrystal and nanocrystal formulations have the same crystal structure, with the main diffraction peaks at 2 theta = 10.4 and 15.3 degrees. The nanocrystal formulation was found to be stable, long-term, when stored at 10 degrees C for up to 6-months. High pressure liquid chromatography (HPLC) of the aqueous humor of rabbit eyes 15-240 mins after the in vivo application of fluorometholone eye drops to the ocular surface revealed that the molecule had been converted to 20 alpha-dihydrofluommetholone (with no evidence of a 20 beta-dihydrofluorometholone fraction), and that penetration was 2-6 fold higher and longer lasting with the nanocrystal, rather than the microcrystal, formulation. In current study we show how newly generated fluommetholone nanocrystals when administered as eye drops enter the anterior chamber of the eye and become metabolized to dihydrofluommetholone.